Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 29, 2025

BUY
$28.04 - $37.2 $86,924 - $115,320
3,100 Added 41.89%
10,500 $341,000
Q1 2025

Jul 16, 2025

BUY
$37.76 - $92.13 $279,424 - $681,762
7,400 New
7,400 $279,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.87B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.